APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hepatitis Drugs Industry Growth and Trends Forecast to 2032

Report ID 173998010122 December 2025101 pages

Choose your research edition.

Industry ResearchHepatitis Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hepatitis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Hepatitis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hepatitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hepatitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatitis Drugs include Johnson & Johnson, Novartis, Merck, GlaxoSmithKline, Abbvie, Vertex Pharmaceuticals, Gilead Sciences, F. Hoffmann-La Roche and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hepatitis Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hepatitis Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatitis Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatitis Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hepatitis Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hepatitis Drugs Market by Company

Johnson & Johnson

Novartis

Merck

GlaxoSmithKline

Abbvie

Vertex Pharmaceuticals

Gilead Sciences

F. Hoffmann-La Roche

Bristol-Myers Squibb

Achillion Pharmaceuticals

Hepatitis Drugs Segment by Type

VIREAD

VICTRELIS

VEMLIDY

TYZEKA

SOVALDI

OLYSIO

INCIVEK

HEPSERA

EPCLUSA

BARACLUDE

Hepatitis Drugs Segment by Application

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

Hepatitis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatitis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hepatitis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of VIREAD Table 2. Major Company of VICTRELIS Table 3. Major Company of VEMLIDY Table 4. Major Company of TYZEKA Table 5. Major Company of SOVALDI Table 6. Major Company of OLYSIO Table 7. Major Company of INCIVEK Table 8. Major Company of HEPSERA Table 9. Major Company of EPCLUSA Table 10. Major Company of BARACLUDE Table 11. Global Hepatitis Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 12. Global Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 13. Global Hepatitis Drugs Sales Market Share in Volume by Type (2021-2026) Table 14. Global Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 15. Global Hepatitis Drugs Sales Market Share in Value by Type (2021-2026) Table 16. Global Hepatitis Drugs Price by Type (2021-2026) & (US$/unit) Table 17. Global Hepatitis Drugs Sales by Type (2027-2032) & (k units) Table 18. Global Hepatitis Drugs Sales Market Share in Volume by Type (2027-2032) Table 19. Global Hepatitis Drugs Sales by Type (2027-2032) & (US$ Million) Table 20. Global Hepatitis Drugs Sales Market Share in Value by Type (2027-2032) Table 21. Global Hepatitis Drugs Price by Type (2027-2032) & (US$/unit) Table 22. North America Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 23. North America Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Europe Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 25. Europe Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Asia-Pacific Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 27. Asia-Pacific Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Latin America Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 29. Latin America Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 30. Middle East and Africa Hepatitis Drugs Sales by Type (2021-2026) & (k units) Table 31. Middle East and Africa Hepatitis Drugs Sales by Type (2021-2026) & (US$ Million) Table 32. Hepatitis Drugs Industry Trends Table 33. Hepatitis Drugs Industry Drivers Table 34. Hepatitis Drugs Industry Opportunities and Challenges Table 35. Hepatitis Drugs Industry Restraints Table 36. Global Hepatitis Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 37. Global Hepatitis Drugs Revenue Market Share by Company (2021-2026) Table 38. Global Hepatitis Drugs Sales by Company (2021-2026) & (k units) Table 39. Global Hepatitis Drugs Sales Share by Company (2021-2026) Table 40. Global Hepatitis Drugs Market Price by Company (2021-2026) & (US$/unit) Table 41. Global Hepatitis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 42. Global Hepatitis Drugs Major Company Production Sites and Headquarters Table 43. Global Hepatitis Drugs Company, Product Type & Application Table 44. Global Hepatitis Drugs Company Establishment Date Table 45. Global Company Market Concentration Ratio (CR5 and HHI) Table 46. Global Hepatitis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 47. Global Hepatitis Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 48. Global Hepatitis Drugs Sales by Region (2021-2026) & (k units) Table 49. Global Hepatitis Drugs Sales Market Share in Volume by Region (2021-2026) Table 50. Global Hepatitis Drugs Sales by Region (2021-2026) & (US$ Million) Table 51. Global Hepatitis Drugs Sales Market Share in Value by Region (2021-2026) Table 52. Global Hepatitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 53. Global Hepatitis Drugs Sales by Region (2027-2032) & (k units) Table 54. Global Hepatitis Drugs Sales Market Share in Volume by Region (2027-2032) Table 55. Global Hepatitis Drugs Sales by Region (2027-2032) & (US$ Million) Table 56. Global Hepatitis Drugs Sales Market Share in Value by Region (2027-2032) Table 57. Global Hepatitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 58. Global Hepatitis Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 59. Global Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 60. Global Hepatitis Drugs Sales Market Share in Volume by Application (2021-2026) Table 61. Global Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 62. Global Hepatitis Drugs Sales Market Share in Value by Application (2021-2026) Table 63. Global Hepatitis Drugs Price by Application (2021-2026) & (US$/unit) Table 64. Global Hepatitis Drugs Sales by Application (2027-2032) & (k units) Table 65. Global Hepatitis Drugs Sales Market Share in Volume by Application (2027-2032) Table 66. Global Hepatitis Drugs Sales by Application (2027-2032) & (US$ Million) Table 67. Global Hepatitis Drugs Sales Market Share in Value by Application (2027-2032) Table 68. Global Hepatitis Drugs Price by Application (2027-2032) & (US$/unit) Table 69. North America Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 70. North America Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Europe Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 72. Europe Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Asia-Pacific Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 74. Asia-Pacific Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Latin America Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 76. Latin America Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 77. Middle East and Africa Hepatitis Drugs Sales by Application (2021-2026) & (k units) Table 78. Middle East and Africa Hepatitis Drugs Sales by Application (2021-2026) & (US$ Million) Table 79. Johnson & Johnson Company Information Table 80. Johnson & Johnson Business Overview Table 81. Johnson & Johnson Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Johnson & Johnson Hepatitis Drugs Product Portfolio Table 83. Johnson & Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Novartis Hepatitis Drugs Product Portfolio Table 88. Novartis Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Merck Hepatitis Drugs Product Portfolio Table 93. Merck Recent Development Table 94. GlaxoSmithKline Company Information Table 95. GlaxoSmithKline Business Overview Table 96. GlaxoSmithKline Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. GlaxoSmithKline Hepatitis Drugs Product Portfolio Table 98. GlaxoSmithKline Recent Development Table 99. Abbvie Company Information Table 100. Abbvie Business Overview Table 101. Abbvie Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Abbvie Hepatitis Drugs Product Portfolio Table 103. Abbvie Recent Development Table 104. Vertex Pharmaceuticals Company Information Table 105. Vertex Pharmaceuticals Business Overview Table 106. Vertex Pharmaceuticals Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Vertex Pharmaceuticals Hepatitis Drugs Product Portfolio Table 108. Vertex Pharmaceuticals Recent Development Table 109. Gilead Sciences Company Information Table 110. Gilead Sciences Business Overview Table 111. Gilead Sciences Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Gilead Sciences Hepatitis Drugs Product Portfolio Table 113. Gilead Sciences Recent Development Table 114. F. Hoffmann-La Roche Company Information Table 115. F. Hoffmann-La Roche Business Overview Table 116. F. Hoffmann-La Roche Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. F. Hoffmann-La Roche Hepatitis Drugs Product Portfolio Table 118. F. Hoffmann-La Roche Recent Development Table 119. Bristol-Myers Squibb Company Information Table 120. Bristol-Myers Squibb Business Overview Table 121. Bristol-Myers Squibb Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Bristol-Myers Squibb Hepatitis Drugs Product Portfolio Table 123. Bristol-Myers Squibb Recent Development Table 124. Achillion Pharmaceuticals Company Information Table 125. Achillion Pharmaceuticals Business Overview Table 126. Achillion Pharmaceuticals Hepatitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Achillion Pharmaceuticals Hepatitis Drugs Product Portfolio Table 128. Achillion Pharmaceuticals Recent Development Table 129. North America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 130. North America Hepatitis Drugs Sales by Country (2021-2026) & (k units) Table 131. North America Hepatitis Drugs Sales Market Share by Country (2021-2026) Table 132. North America Hepatitis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 133. North America Hepatitis Drugs Sales Market Share Forecast by Country (2027-2032) Table 134. North America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. North America Hepatitis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 136. North America Hepatitis Drugs Market Share by Country (2021-2026) Table 137. North America Hepatitis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. North America Hepatitis Drugs Market Share Forecast by Country (2027-2032) Table 139. Europe Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 140. Europe Hepatitis Drugs Sales by Country (2021-2026) & (k units) Table 141. Europe Hepatitis Drugs Sales Market Share by Country (2021-2026) Table 142. Europe Hepatitis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 143. Europe Hepatitis Drugs Sales Market Share Forecast by Country (2027-2032) Table 144. Europe Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Europe Hepatitis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 146. Europe Hepatitis Drugs Market Share by Country (2021-2026) Table 147. Europe Hepatitis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Europe Hepatitis Drugs Market Share Forecast by Country (2027-2032) Table 149. Asia-Pacific Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 150. Asia-Pacific Hepatitis Drugs Sales by Country (2021-2026) & (k units) Table 151. Asia-Pacific Hepatitis Drugs Sales Market Share by Country (2021-2026) Table 152. Asia-Pacific Hepatitis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 153. Asia-Pacific Hepatitis Drugs Sales Market Share Forecast by Country (2027-2032) Table 154. Asia-Pacific Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Asia-Pacific Hepatitis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 156. Asia-Pacific Hepatitis Drugs Market Share by Country (2021-2026) Table 157. Asia-Pacific Hepatitis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Asia-Pacific Hepatitis Drugs Market Share Forecast by Country (2027-2032) Table 159. Latin America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 160. Latin America Hepatitis Drugs Sales by Country (2021-2026) & (k units) Table 161. Latin America Hepatitis Drugs Sales Market Share by Country (2021-2026) Table 162. Latin America Hepatitis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 163. Latin America Hepatitis Drugs Sales Market Share Forecast by Country (2027-2032) Table 164. Latin America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Latin America Hepatitis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 166. Latin America Hepatitis Drugs Market Share by Country (2021-2026) Table 167. Latin America Hepatitis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Latin America Hepatitis Drugs Market Share Forecast by Country (2027-2032) Table 169. Middle East and Africa Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 170. Middle East and Africa Hepatitis Drugs Sales by Country (2021-2026) & (k units) Table 171. Middle East and Africa Hepatitis Drugs Sales Market Share by Country (2021-2026) Table 172. Middle East and Africa Hepatitis Drugs Sales Forecast by Country (2027-2032) & (k units) Table 173. Middle East and Africa Hepatitis Drugs Sales Market Share Forecast by Country (2027-2032) Table 174. Middle East and Africa Hepatitis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 175. Middle East and Africa Hepatitis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 176. Middle East and Africa Hepatitis Drugs Market Share by Country (2021-2026) Table 177. Middle East and Africa Hepatitis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 178. Middle East and Africa Hepatitis Drugs Market Share Forecast by Country (2027-2032) Table 179. Key Raw Materials Table 180. Raw Materials Key Suppliers Table 181. Hepatitis Drugs Distributors List Table 182. Hepatitis Drugs Customers List Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Hepatitis Drugs Image Figure 2. Global Hepatitis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatitis Drugs Sales (2021-2032) & (k units) Figure 5. VIREAD Image Figure 6. Global VIREAD Sales YoY Growth (2021-2032) & (k units) Figure 7. VICTRELIS Image Figure 8. Global VICTRELIS Sales YoY Growth (2021-2032) & (k units) Figure 9. VEMLIDY Image Figure 10. Global VEMLIDY Sales YoY Growth (2021-2032) & (k units) Figure 11. TYZEKA Image Figure 12. Global TYZEKA Sales YoY Growth (2021-2032) & (k units) Figure 13. SOVALDI Image Figure 14. Global SOVALDI Sales YoY Growth (2021-2032) & (k units) Figure 15. OLYSIO Image Figure 16. Global OLYSIO Sales YoY Growth (2021-2032) & (k units) Figure 17. INCIVEK Image Figure 18. Global INCIVEK Sales YoY Growth (2021-2032) & (k units) Figure 19. HEPSERA Image Figure 20. Global HEPSERA Sales YoY Growth (2021-2032) & (k units) Figure 21. EPCLUSA Image Figure 22. Global EPCLUSA Sales YoY Growth (2021-2032) & (k units) Figure 23. BARACLUDE Image Figure 24. Global BARACLUDE Sales YoY Growth (2021-2032) & (k units) Figure 25. Global Hepatitis Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 26. Global Hepatitis Drugs Market Share by Type 2025 VS 2032 Figure 27. North America Hepatitis Drugs Sales Market Share in Volume by Type in 2025 Figure 28. North America Hepatitis Drugs Sales Market Share in Value by Type in 2025 Figure 29. Europe Hepatitis Drugs Sales Market Share in Volume by Type in 2025 Figure 30. Europe Hepatitis Drugs Sales Market Share in Value by Type in 2025 Figure 31. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Type in 2025 Figure 32. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Type in 2025 Figure 33. Latin America Hepatitis Drugs Sales Market Share in Volume by Type in 2025 Figure 34. Latin America Hepatitis Drugs Sales Market Share in Value by Type in 2025 Figure 35. Middle East and Africa Hepatitis Drugs Sales Market Share in Volume by Type in 2025 Figure 36. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Type in 2025 Figure 37. Global Top 5 and 10 Hepatitis Drugs Players Market Share by Revenue in 2025 Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 39. Hepatitis A Image Figure 40. Global Hepatitis A Sales YoY Growth (2021-2032) & (k units) Figure 41. Hepatitis B Image Figure 42. Global Hepatitis B Sales YoY Growth (2021-2032) & (k units) Figure 43. Hepatitis C Image Figure 44. Global Hepatitis C Sales YoY Growth (2021-2032) & (k units) Figure 45. Hepatitis D Image Figure 46. Global Hepatitis D Sales YoY Growth (2021-2032) & (k units) Figure 47. Hepatitis E Image Figure 48. Global Hepatitis E Sales YoY Growth (2021-2032) & (k units) Figure 49. Global Hepatitis Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 50. Global Hepatitis Drugs Market Share by Application 2025 VS 2032 Figure 51. North America Hepatitis Drugs Sales Market Share in Volume by Application in 2025 Figure 52. North America Hepatitis Drugs Sales Market Share in Value by Application in 2025 Figure 53. Europe Hepatitis Drugs Sales Market Share in Volume by Application in 2025 Figure 54. Europe Hepatitis Drugs Sales Market Share in Value by Application in 2025 Figure 55. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Application in 2025 Figure 56. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Application in 2025 Figure 57. Latin America Hepatitis Drugs Sales Market Share in Volume by Application in 2025 Figure 58. Latin America Hepatitis Drugs Sales Market Share in Value by Application in 2025 Figure 59. Middle East and Africa Hepatitis Drugs Sales Market Share in Volume by Application in 2025 Figure 60. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Application in 2025 Figure 61. North America Hepatitis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. North America Hepatitis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. North America Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. North America Hepatitis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Hepatitis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Europe Hepatitis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Europe Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Europe Hepatitis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Hepatitis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Asia-Pacific Hepatitis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Asia-Pacific Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Asia-Pacific Hepatitis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Latin America Hepatitis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 74. Latin America Hepatitis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 75. Latin America Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 76. Latin America Hepatitis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 77. Middle East and Africa Hepatitis Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 78. Middle East and Africa Hepatitis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 79. Middle East and Africa Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 80. Middle East and Africa Hepatitis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 81. Hepatitis Drugs Value Chain Figure 82. Key Raw Materials Price Figure 83. Manufacturing Cost Structure Figure 84. Hepatitis Drugs Production Mode & Process Figure 85. Direct Comparison with Distribution Share Figure 86. Distributors Profiles Figure 87. Years Considered Figure 88. Research Process Figure 89. Key Executives Interviewed

Scope & coverage.

Types
  • VIREAD
  • VICTRELIS
  • VEMLIDY
  • TYZEKA
  • SOVALDI
  • OLYSIO
  • INCIVEK
  • HEPSERA
  • EPCLUSA
  • BARACLUDE
Applications
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • GlaxoSmithKline
  • Abbvie
  • Vertex Pharmaceuticals
  • Gilead Sciences
  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb
  • Achillion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hepatitis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hepatitis Drugs Market by Type
  6. 1.3.1 VIREAD
  7. 1.3.2 VICTRELIS
  8. 1.3.3 VEMLIDY
  9. 1.3.4 TYZEKA
  10. 1.3.5 SOVALDI
  11. 1.3.6 OLYSIO
  12. 1.3.7 INCIVEK
  13. 1.3.8 HEPSERA
  14. 1.3.9 EPCLUSA
  15. 1.3.10 BARACLUDE
  16. 1.4 Global Hepatitis Drugs Market Size by Type
  17. 1.4.1 Global Hepatitis Drugs Market Size Overview by Type (2021-2032)
  18. 1.4.2 Global Hepatitis Drugs Historic Market Size Review by Type (2021-2026)
  19. 1.4.3 Global Hepatitis Drugs Forecasted Market Size by Type (2027-2032)
  20. 1.5 Key Regions Market Size by Type
  21. 1.5.1 North America Hepatitis Drugs Sales Breakdown by Type (2021-2026)
  22. 1.5.2 Europe Hepatitis Drugs Sales Breakdown by Type (2021-2026)
  23. 1.5.3 Asia-Pacific Hepatitis Drugs Sales Breakdown by Type (2021-2026)
  24. 1.5.4 South America Hepatitis Drugs Sales Breakdown by Type (2021-2026)
  25. 1.5.5 Middle East and Africa Hepatitis Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hepatitis Drugs Industry Trends
  2. 2.2 Hepatitis Drugs Industry Drivers
  3. 2.3 Hepatitis Drugs Industry Opportunities and Challenges
  4. 2.4 Hepatitis Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hepatitis Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Hepatitis Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Hepatitis Drugs Price (2021-2026)
  4. 3.4 Global Hepatitis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatitis Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Hepatitis Drugs Company, Product Type & Application
  7. 3.7 Global Hepatitis Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatitis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatitis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatitis Drugs Tier 1, Tier 2, and Tier 3
4 Hepatitis Drugs Regional Status and Outlook
  1. 4.1 Global Hepatitis Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hepatitis Drugs Historic Market Size by Region
  3. 4.2.1 Global Hepatitis Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hepatitis Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hepatitis Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hepatitis Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Hepatitis Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hepatitis Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hepatitis Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hepatitis Drugs by Application
  1. 5.1 Hepatitis Drugs Market by Application
  2. 5.1.1 Hepatitis A
  3. 5.1.2 Hepatitis B
  4. 5.1.3 Hepatitis C
  5. 5.1.4 Hepatitis D
  6. 5.1.5 Hepatitis E
  7. 5.2 Global Hepatitis Drugs Market Size by Application
  8. 5.2.1 Global Hepatitis Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Hepatitis Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Hepatitis Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Hepatitis Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Hepatitis Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Hepatitis Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Hepatitis Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Hepatitis Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Hepatitis Drugs Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Hepatitis Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Hepatitis Drugs Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 GlaxoSmithKline
  20. 6.4.1 GlaxoSmithKline Company Information
  21. 6.4.2 GlaxoSmithKline Business Overview
  22. 6.4.3 GlaxoSmithKline Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline Hepatitis Drugs Product Portfolio
  24. 6.4.5 GlaxoSmithKline Recent Developments
  25. 6.5 Abbvie
  26. 6.5.1 Abbvie Company Information
  27. 6.5.2 Abbvie Business Overview
  28. 6.5.3 Abbvie Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Abbvie Hepatitis Drugs Product Portfolio
  30. 6.5.5 Abbvie Recent Developments
  31. 6.6 Vertex Pharmaceuticals
  32. 6.6.1 Vertex Pharmaceuticals Company Information
  33. 6.6.2 Vertex Pharmaceuticals Business Overview
  34. 6.6.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Vertex Pharmaceuticals Hepatitis Drugs Product Portfolio
  36. 6.6.5 Vertex Pharmaceuticals Recent Developments
  37. 6.7 Gilead Sciences
  38. 6.7.1 Gilead Sciences Company Information
  39. 6.7.2 Gilead Sciences Business Overview
  40. 6.7.3 Gilead Sciences Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Gilead Sciences Hepatitis Drugs Product Portfolio
  42. 6.7.5 Gilead Sciences Recent Developments
  43. 6.8 F. Hoffmann-La Roche
  44. 6.8.1 F. Hoffmann-La Roche Company Information
  45. 6.8.2 F. Hoffmann-La Roche Business Overview
  46. 6.8.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 F. Hoffmann-La Roche Hepatitis Drugs Product Portfolio
  48. 6.8.5 F. Hoffmann-La Roche Recent Developments
  49. 6.9 Bristol-Myers Squibb
  50. 6.9.1 Bristol-Myers Squibb Company Information
  51. 6.9.2 Bristol-Myers Squibb Business Overview
  52. 6.9.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Hepatitis Drugs Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Recent Developments
  55. 6.10 Achillion Pharmaceuticals
  56. 6.10.1 Achillion Pharmaceuticals Company Information
  57. 6.10.2 Achillion Pharmaceuticals Business Overview
  58. 6.10.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Achillion Pharmaceuticals Hepatitis Drugs Product Portfolio
  60. 6.10.5 Achillion Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Hepatitis Drugs Sales by Country
  2. 7.1.1 North America Hepatitis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hepatitis Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Hepatitis Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hepatitis Drugs Market Size by Country
  6. 7.2.1 North America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hepatitis Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Hepatitis Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hepatitis Drugs Sales by Country
  2. 8.1.1 Europe Hepatitis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hepatitis Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Hepatitis Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hepatitis Drugs Market Size by Country
  6. 8.2.1 Europe Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hepatitis Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hepatitis Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hepatitis Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Hepatitis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hepatitis Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hepatitis Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hepatitis Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hepatitis Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hepatitis Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hepatitis Drugs Sales by Country
  2. 10.1.1 South America Hepatitis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hepatitis Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Hepatitis Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hepatitis Drugs Market Size by Country
  6. 10.2.1 South America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hepatitis Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Hepatitis Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hepatitis Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Hepatitis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hepatitis Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hepatitis Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hepatitis Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hepatitis Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hepatitis Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hepatitis Drugs Value Chain Analysis
  2. 12.1.1 Hepatitis Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hepatitis Drugs Production Mode & Process
  7. 12.2 Hepatitis Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hepatitis Drugs Distributors
  10. 12.2.3 Hepatitis Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst